Table 1 Demographic and clinical information for the five included pediatric patients, including two pediatric patients with CF and three pediatric controls (CO).

	CF1	CF2	CO1	CO2	CO3
Age, years	0.9	16.3	0.6	17.6	4.2
Sex	Male	Female	Male	Female	Female
Primary pulmonary diagnosis	Cystic fibrosis	Cystic fibrosis	Bronchomalacia	None	Asthma
CFTR variants	F508del/ R1162X	F508del/ F508del	Unknown	Unknown	K166N
Lowest sweat chloride value (mmol/L)	QNS	84	NP	NP	18
Pancreatic exocrine insufficiency	Yes	Yes	No	No	No
FEV₁, % pred	NP	61	NP	79	NP
Staph aureus colonization	Yes	Yes	No	No	Yes
Pseudomonas colonization	No	No	No	No	No
CFTR modulator use	No	Yes^†	No	No	No
Dornase alfa use	Yes	Yes	No	No	No
Hypertonic saline use	Yes	No	No	No	Yes
Bronchodilator use	Yes	Yes	No	No	Yes
Inhaled antibiotic use	No	No	No	No	No
Oral/IV antibiotics within 6 months	Yes	Yes	No	No	Yes
Inhaled corticosteroid use	Yes	No	No	No	Yes
Oral/IV corticosteroids within 6 months	Yes	No	No	No	Yes

^†CF2 was on elexacaftor-tezacaftor-ivacaftor at the time of flexible bronchoscopy and for over eighteen months prior to the procedure. CFTR: Cystic fibrosis transmembrane conductance regulator; FEV₁, % pred: Forced expiratory volume in one second as percent predicted; IV: Intravenous; NP: Not performed; QNS: Quantity not sufficient.

Quick links

Search